Dravet Syndrome Pipeline Landscape Overview and Outlook 2020 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Dravet Syndrome Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Dravet Syndrome market.

A detailed picture of the Dravet Syndrome pipeline landscape is provided, which includes the disease overview and Dravet Syndrome treatment guidelines. The assessment part of the report embraces in-depth Dravet Syndrome commercial assessment and clinical assessment of the Dravet Syndrome pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dravet Syndrome collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The report provides insights into:

• All of the companies that are developing therapies for the treatment of Dravet Syndrome with aggregate therapies developed by each company for the same.
• Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Dravet Syndrome treatment.
• Dravet Syndrome key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Dravet Syndrome market.

Key Topics Covered

1. Report Introduction

2. Dravet Syndrome

2.1. Overview

2.2. History

2.3. Dravet Syndrome Symptoms

2.4. Causes

2.5.Pathophysiology

2.6. Dravet Syndrome Diagnosis

2.6.1. Diagnostic Guidelines

3. Dravet Syndrome Current Treatment Patterns

3.1. Dravet Syndrome Treatment Guidelines

4. Dravet Syndrome - Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Dravet Syndrome companies collaborations, Licensing, Acquisition - Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Dravet Syndrome Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. Dravet Syndrome Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. Dravet Syndrome Late Stage Products (Phase-III)

7. Dravet Syndrome Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Dravet Syndrome Discontinued Products

13. Dravet Syndrome Product Profiles

13.1. Drug Name: Company

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

14. Dravet Syndrome Key Companies

15. Dravet Syndrome Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products

16.2.1. Reasons for the discontinuation

17. Dravet Syndrome Unmet Needs

18. Dravet Syndrome Future Perspectives

19. Dravet Syndrome Analyst Review

Companies Mentioned

• Zogenix Inc.
• Takeda
• Ovid Therapeutics Inc.
• Epygenix
• NYU Langone Health
• PTC Therapeutics
• GW Research Ltd.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/iwubty